Navigation Links
Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx
Date:3/7/2012

g the discovery, development, activity, therapeutic potential and safety of ISIS-STAT3Rx and the therapeutic benefit of antisense drugs that incorporate Isis' Generation 2.5 chemistry.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc., its jointly owned subsidiary.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.

                        
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Initiates Plans for China Office
2. American Regent Initiates Nationwide Voluntary Recall of Phenylephrine HCl Injection, USP, 1%, 5 mL Vial, Lot# 0693, Due to Visible Particles
3. Echo Therapeutics Initiates Clinical Trials of its Symphony tCGM System in Critical Care Patients
4. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
6. Sumagen Initiates Clinical Testing of Omnia Biologics Manufactured HIV Vaccine
7. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
8. Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program
9. Isis Initiates Phase 1 Clinical Study of ISIS-SMNRx in Patients With Spinal Muscular Atrophy
10. Soligenix Initiates Next Generation Anthrax Vaccine Development Program Under Agreement With Harvard University
11. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... Juli 2015 Sequent Medical, ein ... Entwicklung innovativer Geräte für die Behandlung neurovaskulärer ... von R. Michael Kleine in den ... verfügt über eine mehr als 25-jährige Erfahrung ... hat verschiedene globale biomedizinische Unternehmen erfolgreich geleitet ...
(Date:7/7/2015)... Accelovance, Inc. (Accelovance), a global contract ... General Medicine announced the completion of enrollment and ... Therapeutics, Inc. for the Phase 3 trial of ... SUSTOL® (granisetron injection, extended release) as part of ... receptor antagonist fosaprepitant and IV corticosteroid dexamethasone ...
(Date:7/7/2015)... DUBLIN , June 30, 2015 ... has announced the addition of the "Deciphering ... Strategies" report to their offering. ... pharmaceutical companies have been involved in a series ... patent cliff has resulted in significant overcapacities in ...
Breaking Medicine Technology:Sequent Medical beruft Mike Kleine in den Aufsichtsrat 2Sequent Medical beruft Mike Kleine in den Aufsichtsrat 3Accelovance Completes Trial Enrollment and Delivery of Clinical Data for Heron Therapeutics' Phase 3 Trial 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3
... Musculoskeletal Transplant Foundation (MTF) has announced the release of two ... The new sizes--16cm x 20cm and 20cm x 20cm--are being ... their patients. This unique human dermal allograft is specifically prepared ... has been a year since MTF introduced its bi-lateral breast ...
... -- Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) ("Lotus" or the ... and drugs in the People,s Republic of China ("PRC"), ... its Inner Mongolia branch company, including land use right ... Inner Mongolia, in order to focus its business on ...
Cached Medicine Technology:New, Larger, Bilateral Breast Graft Kits Announced by MTF 2Lotus Pharmaceuticals Announces Business Reorganization and Provides Updates on the Beijing Headquarters Building 2Lotus Pharmaceuticals Announces Business Reorganization and Provides Updates on the Beijing Headquarters Building 3
(Date:7/7/2015)... ... July 07, 2015 , ... Safe Catch is setting revolutionary purity limits ... Albertsons, Gelson’s Markets, New Leaf Community Markets, Sprouts Farmers Market and Wegmans are some ... technology to test every fish for mercury,” said Safe Catch co-founder Sean Wittenberg. “We ...
(Date:7/7/2015)... ... ... and guardians of teenagers or young adults will be interested in reading the latest ... alcohol abuse located in Southwest Michigan. A recently released study by New York University’s ... “club drug” use among high school seniors. The blog post offers guidance to parents ...
(Date:7/7/2015)... Angeles, CA (PRWEB) , ... July 07, 2015 , ... ... special promotion on teeth whitening treatments. A professional teeth whitening is one of the ... person’s appearance, as well as they can decrease smile satisfaction and confidence. With the ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... Whole Health (NIWH) have jointly announced a partnership focused on providing knowledge ... medical case studies. The study will be conducted with NIWH trained patient health ...
(Date:7/7/2015)... ... ... On May 29, 2015, Health Canada announced that they had registered a Marketing ... free oats and foods that contain them as ingredients. , “We are very excited ... gluten-free oat products in Canada,” says Frank Massong, VP of Regulatory and Technical Services ...
Breaking Medicine News(10 mins):Health News:Safe Catch Launches Tuna with Lowest Mercury Limit of Any Brand 2Health News:A Forever Recovery Releases New Information on “Club Drugs” and Tips for Parents of Teens and Young Adults 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 3Health News:Isabel Healthcare and the National Institute of Whole Health Announce Partnership for a Pilot Study Using the Isabel Diagnostic Support Tool and Knowledge Organizer 2Health News:Isabel Healthcare and the National Institute of Whole Health Announce Partnership for a Pilot Study Using the Isabel Diagnostic Support Tool and Knowledge Organizer 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 4
... According to Millennium Research Group (MRG), the global authority ... is putting pressure on publicly-funded health care systems across ... prices in the region. MRG,s European Markets ... report details the extent to which competitive pricing ...
... ... world,s leading manufacturer and distributor of automated blood pressure monitors and health testing stations, ... ... -- Lifeclinic International has named Lon von Hurwitz Executive Vice President of ...
... Spine announced today that the U.S. Food and Drug ... FS3 Minimally Invasive Spinal System. , , Available ... System offers cannulated wire guided Minimally Invasive Surgery implants ... through a percutaneous or open approach. Intuitive design allows ...
... levels play a part in the connection , THURSDAY, July 9 ... bit of good news: New research shows that your risk of ... , And, no matter what a woman,s age or what migraine ... is still reduced, according to the study, which appears in the ...
... NEW YORK, July 9 ... for ways to remain financially afloat. Some are forced ... as health,care and medications, are being sacrificed and the ... mean the difference between,staying healthy and developing a debilitating ...
... new company in the U.S. to help sick or handicapped ... out this mission everywhere. , , Three Wishes, Inc., ... oxygen, to grooming and sickroom and bathroom equipment, all designed ... , , The company has a mission to help ...
Cached Medicine News:Health News:European Health Care Institutions Forced to Select Lower-Priced Interventional Cardiology Devices 2Health News:Pioneer of Digital Place-Based Media Joins World's Leading Blood Pressure and Health Kiosk Manufacturer 2Health News:Migraines Linked to Reduced Breast Cancer Risk 2Health News:Keep Healthy in a Poor Economy 2Health News:Keep Healthy in a Poor Economy 3
... is a 1-step, hand-held, point-of-care device for the ... human urine. The TOX/See device can detect ... drugs in 3 to 8 minutes and requires ... cassette is individually packaged to maximize convenience and ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
... a 1-step, hand-held, point-of-care device for the qualitative ... urine. The TOX/See device can detect up ... in 3 to 8 minutes and requires only ... is individually packaged to maximize convenience and ease ...
Medicine Products: